Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2024-05-20 00:00:00 ET · period of report 2024-05-16 · accession 0001593968-24-000715 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-20 | 2024-05-16 | ALLO | Parker Geoffrey M. | CFO | A - Grant | $2.90 | +344.8K | 1.16M | +42% | +$1.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-16 | A | A | 344,828 | $2.90 | 1,164,418 | D | — | — | (F1) These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the "Issuer") in a registered direct offering. |